Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 2, 2002, Pages 849-857

  Chen, Weiqing ^a   Yang, Jerry Z ^a   Andersen, Rikke ^a   Nielsen, Lisbeth H ^b   Borchardt, Ronald T ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DIAZEPAM; ELACRIDAR; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; OPIATE PEPTIDE; PRODRUG; QUINIDINE; SUCROSE; TRITIUM;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ACRIDINES; ALGORITHMS; ANIMALS; BIOTRANSFORMATION; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAZEPAM; ENKEPHALIN, LEUCINE-2-ALANINE; GABA MODULATORS; ISOQUINOLINES; KINETICS; MALE; MASS SPECTROMETRY; P-GLYCOPROTEIN; PERFUSION; PRODRUGS; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES;

EID: 0036827575     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037143     Document Type: Article

References (30)

1. Anderson BD (1996) Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 19:171-202.
2. Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, and Borchardt RT (1999a) Acyloxy-alkoxy-based cyclic prodrugs of opioid peptides: Evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm Res 16:24-29.
3. Bak A, Siahaan TJ, Gudmundsson OS, Gangwar S, Friis GJ, and Borchardt RT (1999b) Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker. J Pept Res 53:393-402.
4. Borst P and Schinkel H (1998) P-glycoprotein, a guardian of the brain, in Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology (Pardridge WR ed) pp 198-206, Cambridge University Press, Cambridge.
5. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
6. Crone C and Levitt DG (1984) Capillary permeability to small solutes, in Handbook of Physiology, Section 2: Part 1 (Renkin EM and Michel CC eds) pp 411-466, American Physiological Society, Bethesda, MD.
7. 5-enkephalin. Eur J Pharmacol 47:223-225.
8. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
9. Iyengar S, Kim HS, and Wood PL (1987) μ-, δ-, κ- and ε-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: Subchronic tolerance studies of endogenous opioid peptides. Brain Res 435:220-226.
10. Jette L and Beliveau R (1993) P-glycoprotein is strongly expressed in brain capillaries, in Frontiers in Cerebral Vascular Biology: Transport and Its Regulation (Drewes LR and Betz AL eds) pp 121-125, Plenum Press, New York.
11. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, and Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580.
12. Metzer H, Heuber-Metzer S, Steinacker A, and Struber J (1980) Staining PO2 measurement sites in the rat brain and quantitative morphometry of the surrounding capillary. Pfluegers Arch 388:21-27.
13. Ouyang H, Borchardt RT, Siahaan TJ, and Vander Velde D (2002a) Synthesis and conformation study of a coumarinic acid-based cyclic prodrug of opioid peptide with modified sensitivity to esterase-catalyzed bioconversion. J Pept Res 59:183-195.
14. Ouyang H, Tang F, Siahaan T, and Borchardt RT (2002b) A modified coumarinic acid-based cyclic prodrug of an opioid peptide: Its enzymatic and chemical stability and cell permeation characteristics. Pharm Res 19:794-801.
15. Pauletti GM, Gangwar S, Siahaan T, Aubé J, and Borchardt RT (1997) Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 27:235-256.
16. Prokai-Tatrai K, Prokai L, and Bodor N (1996) Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med Chem 39:4775-4782.
17. Rapoport SI, Ohno K, and Pettigrew KD (1979) Drug entry into the brain. Brain Res 172:354-359.
18. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, and Roux F (1998) Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-715.
19. Seelig A, Blatter XL, and Wohnsland F (2000) Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharmacol Ther 38:111-121.
20. Seelig A and Landwojtowicz E (2000) Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40.
21. Smith QR (1996) Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system, in Models for Assessing Drug Absorption and Metabolism (Borchardt RT, Smith PL, and Wilson G eds) pp 285-307, Plenum Press, New York.
22. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.
23. Tang F and Borchardt RT (2002a) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE. Pharm Res 19:780-786.
24. Tang F and Borchardt RT (2002b) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res 19:787-793.
25. Triguero D, Buciak J, and Pardridge WM (1990) Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54:1882-1888.
26. Voigt W, Mannhold R, Limberg J, and Blaschke G (1988) Interactions of antiarrhythmics with artificial phospholipid membranes. J Pharm Sci 77:1018-1020.
27. Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T, and Borchardt RT (1999) Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers. J Pept Res 53:370-382.
28. Yang JZ, Bastian KC, Moore RD, Stobaugh JF, and Borchardt RT (2002a) Quantitative analysis of a model opioid peptide and its cyclic prodrugs in rat plasma using high-performance liquid chromatography with fluorescence and tandem mass spectrometric detection. J Chromatogr B, in press.
29. Yang JZ, Chen W, and Borchardt T (2002b) In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J Pharmacol Exp Ther 303:840-848.
30. Zhang Y, Han H, Elmquist WF, and Miller DW (2000) Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 876:148-153.